- One of bioMérieux's fastest-growing business segments is PCR tests
- The company is well-placed to benefit from structural growth drivers such as the move towards personalised medicine and need to reduce healthcare costs
Lorna Logan, co-manager of Stewart Investors European Sustainability Fund (IE00BN2B0908), explains why she invests in French healthcare equipment company bioMérieux (FRA:BIM).
“bioMérieux makes testing equipment used to diagnose infectious diseases, screen for cancer and detect microorganisms in food, pharmaceutical and cosmetic products. The company has been a pioneer in the field of diagnostics for over 55 years with a steadfast mission to improve patient outcomes, increase laboratory efficiency and protect the health of people around the world.